Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Cantor starts vTv at OW; PT $5

Cantor Fitzgerald launched coverage of vTv Therapeutics (NASDAQ:VTVT) with an “overweight” rating and 12-month price target of $5. The stock closed at 71 cents on Feb. 17. vTv is developing novel orally administered...

February 18, 2022

Markets

AGP ups T2 BioSystems to buy; Canaccord cuts PT to $1.50 from $3

Following the fourth quarter report for T2 BioSystems (NASDAQ:TTOO), Alliance Global Partners upgraded T2 to “buy” from “neutral” and raised its price target to 70 cents from 55 cents, while Canaccord Genuity reduced...

February 18, 2022

Markets

Cantor starts Oramed at OW; PT $20

Cantor Fitzgerald launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMP) with an “overweight” rating and price target of $20. The stock closed at $10.63 on Feb. 17. Oramed is a developing novel drug formulations for...

February 18, 2022

Developments

180 Life Sciences forms scientific advisory board

180 Life Sciences (NASDAQ:ATNF) formed a scientific advisory board (SAB) whose initial composition will include Prof. Raphael Mechoulam of Hebrew University, Israel; Dr. Kevin Tracey, of Hofstra/Northwell; Prof. Irene...

February 17, 2022

Developments

Revive gets FDA orphan drug nod for Bucillamine in IRI during liver transplant

Revive Therapeutics (OTCQB:RVVTF; CSE:RVV; FRANKFURT:31R) received orphan drug designation from the FDA for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. ...

February 15, 2022

Executive Moves

Hepion names world-renowned hepatologist, Dr. Eddie Cheung, to lead strategic medical affairs in Asia

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Eddie Cheung, M.D., FACG, to lead the company’s strategic medical affairs in Asia, a newly-created position. Dr. Cheung will explore and identify possible...

February 15, 2022

Markets

Cantor ups Collegium Pharma to OW; PT to $26 from $17

Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International. Shares...

February 14, 2022

Developments

Altamira Therapeutics completes enrollment in Phase 2 acute vertigo trial

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment in Part B of the Phase 2 TRAVERS clinical trial evaluating intranasal betahistine (AM-125) in acute vertigo. The company expects to release top-line...

February 14, 2022

Markets

Brookline starts Caribou Biosciences at buy; PT $19

Brookline Capital Markets initiated coverage of Caribou Biosciences (NASDAQ:CRBU) with a “buy” rating and 12-to-18-month price target of $19. The stock closed at $10.71 on Feb. 11. Caribou is a leading next...

February 14, 2022

Markets

BTIG starts Aerovate Therapeutics at buy; PT $24

BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...

February 11, 2022

Developments

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and...

February 9, 2022

Markets

Maxim starts SeqLL at buy; PT $3

Maxim Group initiated coverage of SeqLL (NASDAQ:SQL) with a “buy” rating and price target of $3. The stock closed at $1.60 on Feb. 8. SeqLL is developing true single molecule sequencing (tSMS), a type of short-read...

February 9, 2022

Subscribe